Telavancin vs. linezolid in an animal model of severe MRSA pneumonia
D. Battaglini (Genova, Italy), G. Li Bassi (Barcelona, Spain), F. Pagliara (Genova, Italy), A. Meli (Milano, Italy), H. Yang (Barcelona, Spain), M. Yang (Barcelona, Spain), A. Motos (Barcelona, Spain), J. Bobi (Barcelona, Spain), E. Aguilera (Barcelona, Spain), T. Senussi (Genova, Spain), J. Miller (Barcelona, Spain), L. Fernandez (Barcelona, Spain), E. Barbeta Viñas (Barcelona, Spain), A. Torres (Barcelona, Spain)
Source: International Congress 2018 – New therapies for respiratory infections: experimental and translational studies
Disease area: Respiratory infections
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
D. Battaglini (Genova, Italy), G. Li Bassi (Barcelona, Spain), F. Pagliara (Genova, Italy), A. Meli (Milano, Italy), H. Yang (Barcelona, Spain), M. Yang (Barcelona, Spain), A. Motos (Barcelona, Spain), J. Bobi (Barcelona, Spain), E. Aguilera (Barcelona, Spain), T. Senussi (Genova, Spain), J. Miller (Barcelona, Spain), L. Fernandez (Barcelona, Spain), E. Barbeta Viñas (Barcelona, Spain), A. Torres (Barcelona, Spain). Telavancin vs. linezolid in an animal model of severe MRSA pneumonia. 5457
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: